• FirefoxInstall the new Firefox »
  •  Dow Down0.38% Nasdaq Down0.53%

    Amgen Inc. (AMGN)

    -NasdaqGS
    158.23 Down 1.40(0.88%) 10:25AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Amgen Inc.
    One Amgen Center Drive
    Thousand Oaks, CA 91320
    United States - Map
    Phone: 805-447-1000
    Fax: 805-447-1010
    Website: http://www.amgen.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:17,900

    Business Summary 

    Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Amgen Inc.

    Corporate Governance 
    Amgen Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Robert A. Bradway , 52
    Chairman, Chief Exec. Officer, Pres, Chairman of Exec. Committee and Member of Equity Award Committee
    5.65M0.00
    Mr. Madhavan Balachandran , 64
    Exec. VP of Operations
    2.57M1.30M
    Dr. Sean E. Harper M.D., 52
    Exec. VP of R&D
    2.66M447.00K
    Mr. Anthony C. Hooper , 60
    Exec. VP of Global Commercial Operations
    2.98M0.00
    Mr. David W. Meline , 58
    Chief Financial Officer and Exec. VP
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders